强生股价2026年2月12日上涨0.57%，业绩与行业地位支撑表现

Core Insights - Johnson & Johnson (JNJ) stock price showed strong performance on February 12, 2026, closing at $242.24, up 0.57%, but did not surpass its historical high of approximately $250 set in December 2025 [1] - The company reported Q4 2025 revenue of $24.56 billion, a year-over-year increase of 9.08%, with adjusted earnings per share of $2.46, exceeding market expectations [2] - Johnson & Johnson maintained its position as the world's largest pharmaceutical company in 2025 with revenue of $94.193 billion, driven by a 95.9% increase in oncology drug revenue [3] - As of February 2026, 57% of 28 institutions rated the stock as "buy" or "hold," with a target average price of $237.48, slightly below the current stock price [4] - Market attention is focused on the January CPI data to be released on February 14, which could impact interest rate expectations and the attractiveness of high-dividend stocks [5] Performance Summary - Q4 2025 revenue was $24.56 billion, with a 9.08% year-over-year growth and adjusted EPS of $2.46, surpassing market forecasts [2] - The company expects 2026 revenue to be between $99.5 billion and $100.5 billion, with adjusted EPS guidance of $11.43 to $11.63, both above Wall Street expectations [2] Industry Position - Johnson & Johnson led the global pharmaceutical industry in 2025 with $94.193 billion in revenue, highlighting the strength of its innovative pipeline, particularly in oncology [3] - The company has mitigated tariff pressures through a drug pricing agreement with the U.S. government, absorbing "hundreds of millions" in price reduction impacts while maintaining profit growth resilience [3]